Behind the Prescription Pad: The Impact of Pharma’s Reputation on HCPs’ Prescribing Decisions

Two-thirds of surveyed HCPs said that they are reluctant to prescribe medications from pharma and biotech companies with a less than stellar reputation.

A study found Healthcare professionals (HCP) consider corporate reputation the leading factor when it comes to prescribing decisions, outside of a medication’s functional abilities, a study released Tuesday morning found. 

The study surveyed more than 1,000 HCPs around the world to evaluate which factors influence their perceptions of biotech and pharma brands as well as how this impacts their prescribing decisions. 

Two-thirds of respondents said that they are reluctant to prescribe medications from pharma and biotech companies with a less than stellar reputation. The study also indicated that when treatments have similar profiles, a drugmaker’s reputation is the differentiating factor among HCPs. 

Ninety percent of respondents said that these healthcare companies should support improving patient outcomes in ways that go beyond high-quality drug therapies, while nearly three-quarters said brands should add value beyond providing goods and services.

The big lesson from the survey is that pharma and biotech brands should prioritize the development of corporate reputation programs focusing on thought leadership, medical education for HCPs professionals and advocacy for patients.

It also shows that the goodwill and positive reputational gains that pharma and biotech brands received during the COVID-19 pandemic have started to wane, adding that the industry is at “an important crossroads” to maintain confidence among HCPs. 

HCPs want pharma to go beyond medicine and address the entire healthcare experience, from education and support right through to tackling societal and environmental issues,” Hudson said in a statement. 

When it comes to what HCPs value most in a healthcare brand, it’s of little surprise that patient-centricity is the top consideration, followed by being innovative and progressive. 

These HCPs also said they expect the industry to offer patient support programs, improve the understanding of health information that is oftentimes complex in nature and demonstrate an understanding of the lived patient experience.

.

Source/Inspiration.

0+

YEARS IN

MARKET

0+

THERAPY

AREAS

WORK IN

0+

COUNTRIES


GET IN TOUCH

Whether you’re looking for effective solutions to transition F2F meetings to a virtual or online environment, support with clinical trials, medical advisory boards, symposia, key opinion leader (KOL) management, internal medical training, medical writing or speaker training programs and more, count on our 16-year experience and expertise over 40 therapeutic areas.

SDM also offers strategic consulting services and can help with communication and engagement of your target audiences as part of market development opportunities.

Discover why over 95% of clients are “Extremely Satisfied” with SDM and over 90% say the agency deliver “Much more than expected”.